{"ticker": {"uuid": "99a6156c-d9f9-4f15-bdbc-2429eaeb120d", "symbol": "VIR", "name": "Vir Biotechnology Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. $VIR Shares Bought by Candriam S.C.A.", "summary": "Candriam S.C.A. increased its stake in Vir Biotechnology (NASDAQ:VIR) by 10.1% in the first quarter, holding over 1.1 million shares valued at approximately $10.2 million. Other institutional investors also adjusted their positions, resulting in 65.32% institutional ownership. Wh", "url": "https://www.marketbeat.com/instant-alerts/filing-vir-biotechnology-inc-vir-shares-bought-by-candriam-sca-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T08:40:38", "published_display": "13 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Y Intercept Hong Kong Ltd Takes Position in Vir Biotechnology, Inc. $VIR", "summary": "Y Intercept Hong Kong Ltd disclosed a new position in Vir Biotechnology, Inc. by purchasing 134,547 shares valued at approximately $1.2 million, now owning 0.08% of the company. Vir Biotechnology shares recently traded down, sitting below its 52-week high, and the company reporte", "url": "https://www.marketbeat.com/instant-alerts/filing-y-intercept-hong-kong-ltd-takes-position-in-vir-biotechnology-inc-vir-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T18:38:59", "published_display": "12 Jul 2026 18:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Vir Biotechnology, Inc. (VIR)", "summary": "This article analyzes the historical stock performance of Vir Biotechnology, Inc. (VIR). It calculates the returns on hypothetical $1,000 investments made one and five years ago, showing disparate outcomes. The article also provides an overview of Vir Biotechnology's focus on inf", "url": "https://www.stocktitan.net/tools/stock-return-calculator/VIR", "source_name": "Stock Titan", "published_at": "2026-07-04T09:09:43", "published_display": "04 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SA", "summary": "Pictet Asset Management Holding SA significantly increased its stake in Vir Biotechnology (NASDAQ:VIR) by 10,878.9% in Q1, now owning 1.48 million shares worth $13.3 million. This increase comes despite Vir Biotechnology reporting weaker than expected quarterly results and analys", "url": "https://www.marketbeat.com/instant-alerts/filing-vir-biotechnology-inc-vir-stock-holdings-increased-by-pictet-asset-management-holding-sa-2026-07-03/", "source_name": "MarketBeat", "published_at": "2026-07-03T09:11:13", "published_display": "03 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIR - Vir Biotechnology Inc Latest SEC Filings", "summary": "This page provides an overview of Vir Biotechnology Inc (VIR) focusing on its latest SEC filings and comprehensive financial data. It includes key stock performance metrics, valuation ratios, and insider/institutional ownership percentages, alongside recent earnings figures and a", "url": "https://finviz.com/stock?t=VIR&p=m&ty=lf&r=max&page=13", "source_name": "Finviz", "published_at": "2026-07-02T11:11:49", "published_display": "02 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Announces Proposed Public Offering of Common Stock", "summary": "Vir Biotechnology, a clinical-stage biopharmaceutical company, announced its intention to offer $200,000,000 of common stock in an underwritten public offering. The company will also grant underwriters a 30-day option to purchase an additional $30,000,000 of shares. The offering ", "url": "https://www.natlawreview.com/press-releases/vir-biotechnology-announces-proposed-public-offering-common-stock", "source_name": "The National Law Review", "published_at": "2026-07-01T08:10:02", "published_display": "01 Jul 2026 08:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Vir Biotechnology For: 29 June By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing by Vir Biotechnology for June 29. It includes the stock symbol VIR and its performance on that date, amidst various market data and other news. The content primarily serves as a placeholder for the filing information, a", "url": "https://ng.investing.com/news/stock-market-news/form-144-vir-biotechnology-for-29-june-93CH-2578668", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T19:39:26", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OP Asset Management Ltd Takes Position in Vir Biotechnology, Inc. $VIR", "summary": "OP Asset Management Ltd has acquired a new position in Vir Biotechnology, purchasing 113,028 shares valued at approximately $1.013 million in the first quarter of 2026. This move comes as institutional investors now own 65.32% of the company's shares. Despite a recent weak quarte", "url": "https://www.marketbeat.com/instant-alerts/filing-op-asset-management-ltd-takes-position-in-vir-biotechnology-inc-vir-2026-06-30/", "source_name": "MarketBeat", "published_at": "2026-06-30T09:09:54", "published_display": "30 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Vir Biotechnology, Inc. SEC Filing", "summary": "This article reports on Vir Biotechnology, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details include the sale of 16,000 shares of common stock acquired through a stock option exercise, with an aggregate market value of $165,138.95, and ", "url": "https://www.stocktitan.net/sec-filings/VIR/144-vir-biotechnology-inc-sec-filing-c016dfa796b3.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:40:30", "published_display": "29 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Vir Biotechnology, Inc. \u2013 NASDAQ:VIR", "summary": "This article provides financial information for Vir Biotechnology, Inc. (NASDAQ: VIR), specifically focusing on its forward price-to-sales ratio. It appears to be a financial data point or a report generated by TradingView, detailing a specific period's value, change, and percent", "url": "https://www.tradingview.com/symbols/NASDAQ-VIR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:24", "published_display": "26 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Vir Biotechnology, Inc. (VIR) stock, including analyst price targets, current stock performance, and financial data. It highlights that the 9 analysts have a price target of 21.56 USD with a maximum estimate of 30.00 USD and a minimum of 16.00", "url": "https://www.tradingview.com/symbols/NASDAQ-VIR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:23", "published_display": "26 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Vir Biotechnology, Inc. \u2013 NASDAQ:VIR", "summary": "This article focuses on the enterprise value to EBIT forward metric for Vir Biotechnology, Inc. (NASDAQ: VIR). It directly presents the financial data for this specific metric without further analysis or commentary within the provided content. The details are presented in a strai", "url": "https://www.tradingview.com/symbols/NASDAQ-VIR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:09:37", "published_display": "26 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIR: Hepatitis Delta Program And Oncology Partnership Will Drive Future Upside", "summary": "Analysts have increased their average price target for Vir Biotechnology to $21.56, up from $20.67, driven by an improved revenue growth outlook and a higher future P/E assumption, factoring in the potential of emerging hepatitis delta virus therapies. The company is advancing in", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/p3tydi5d-strong-clinical-advances-in-oncology-and-hepatitis-delta-will-secure-future-success/updates/17-analysts-have-lifted-the-average-price-target-for-vir-biotec", "source_name": "Simply Wall Street", "published_at": "2026-06-23T17:09:37", "published_display": "23 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Inc (VIR) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Vir Biotechnology Inc (VIR) has a current risk assessment score of 4.70, placing it 67th out of 389 in the Biotechnology & Medical Research industry. The company's beta of 1.66 indicates higher volatility compared to the S&P 500. The report details various risk metrics including ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vir/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-23T08:40:53", "published_display": "23 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Inc (VIR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Vir Biotechnology Inc (VIR), giving it a current financial score of 7.47, ranking it 116 out of 389 in its industry. The company shows stable financial status and high operating efficiency. However, its latest quarterly revenue decrea", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vir/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T08:09:48", "published_display": "23 Jun 2026 08:09", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of \"Moderate Buy\" by Brokerages", "summary": "Vir Biotechnology, Inc. (NASDAQ:VIR) has received a consensus \"Moderate Buy\" rating from nine brokerages, with an average 1-year price target of $20.88. Recent analyst updates were largely positive, including increased price targets from several firms, though Weiss Ratings mainta", "url": "https://www.marketbeat.com/instant-alerts/vir-biotechnology-inc-nasdaqvir-given-average-recommendation-of-moderate-buy-by-brokerages-2026-06-22/", "source_name": "MarketBeat", "published_at": "2026-06-22T06:39:24", "published_display": "22 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology (VIR) Stock Could Be 56% Undervalued After New PSMA Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOVTJhTXA4amtuREtjcW5TR1dBRTlUWW5EcDNuT0tqUHNoN0FqWXNfQ3BVRjczVWJIbXZZY2hPQjV2d1A2cEVDX0o0TVZKRl9NY0FqeThubDlSZkNlU3ItdmNwNV9wV0dkdVVzWkdjelJyMkNzZzIwZDVzN2lqMnRLYkJFZzlVZkV5RzZIMF9WdllFX0JEMXczUC0wMUhQMFNJQUwyeVY4dUN5M3I0dU1jN3p3SUVIMU1xaXhmRzhveDIwV0k4NXVmcnQycGJRMGxxbjRmLVRGYVRzNmlzaG1wX0tYeW_SAeoBQVVfeXFMT2plSEpSQ0RSaFRERjU4bFdYN01KdWhyd0YtMV9Dbko3bjhVaFRhQ3R0bnlGVEZmSzBzRC1KUTRqVFduUENrcDd4Vms3ZHYySXdsTVlnSXo5ekIycVZuS1B0SGRxVXB6U3VKSWxvN1dZSldtVm1UeFlicFVDLUpLSDNjWHdiVnhRZ0hodVpodDZGdmV4T2tYR2VoVTRERDJ6NTZsSlpfbHNucy1xQnFGQ2NBaTQzTWo5NkgzM2daU3R0WUYzalpJT2VSTVRFRTdfOGpyNWdlQUJGWWZQZHJLWUY3ODFmXzIwclFn?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vir Biotechnology (VIR) Quietly Recasting Its Governance Strength With a New Audit Committee Chair?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTFBLTlZKRkozaEk4eERFcjZIb0ZibktCNnJNSkVzdmhCd0ZFRzROcll0TjJiTVBqeG5iWlhlSlFybFdsdkV4Qkw5RFB5Wmd5MDBkbFZ2Z1NZX1ZfV1pxcGNjZFk1dEZjR21FRWNUQ2RqOA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T05:53:20+00:00", "published_display": "18 Jun 2026 05:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Vir Biotechnology Inc (VIR), noting that relevant data for business segments, regional revenue, and profit contribution for FY2025 has not yet been disclosed by the company. It indicates that the United States contribu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vir/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T05:11:06", "published_display": "17 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants", "summary": "Vir Biotechnology director Timothy Coughlin has been granted restricted stock units (RSUs) and stock options. He received two RSU awards of 8,000 shares each and two stock option grants covering 16,000 shares each, with an exercise price of $8.51 per share, expiring in 2036. Thes", "url": "https://www.stocktitan.net/sec-filings/VIR/form-4-vir-biotechnology-inc-insider-trading-activity-f2f5d00ba14f.html", "source_name": "Stock Titan", "published_at": "2026-06-12T17:09:37", "published_display": "12 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology (VIR) director Coughlin reports zero share ownership", "summary": "Vir Biotechnology director Timothy Coughlin filed an initial Form 3, reporting zero beneficial ownership of the company's common stock as of June 9, 2026. This SEC filing establishes his initial position as an insider, showing no direct holdings. A Form 3 is required when an indi", "url": "https://www.stocktitan.net/sec-filings/VIR/form-3-vir-biotechnology-inc-initial-statement-of-beneficial-ownershi-09a23817212a.html", "source_name": "Stock Titan", "published_at": "2026-06-11T22:40:06", "published_display": "11 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00", "summary": "Morgan Stanley has increased its price target for Vir Biotechnology (NASDAQ:VIR) to $27.00 from $23.00, maintaining an \"overweight\" rating. This adjustment suggests a potential upside of 227.27% from the current stock price. Despite weak recent earnings, insider selling, and mixe", "url": "https://www.marketbeat.com/instant-alerts/morgan-stanley-raises-vir-biotechnology-nasdaqvir-price-target-to-2700-2026-06-11/", "source_name": "MarketBeat", "published_at": "2026-06-11T13:09:00", "published_display": "11 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors", "summary": "Vir Biotechnology, Inc. announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. Mr. Coughlin, former CFO of Neurocrine Biosciences, Inc., brings extensive financial and operational experience across the ", "url": "https://www.businesswire.com/news/home/20260610324261/en/Vir-Biotechnology-Announces-Appointment-of-Timothy-Coughlin-to-its-Board-of-Directors", "source_name": "Business Wire", "published_at": "2026-06-11T11:39:33", "published_display": "11 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology appoints Timothy Coughlin to board", "summary": "Vir Biotechnology (NASDAQ:VIR) has announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026. Coughlin brings extensive financial and biotechnology experience, having previously served as CFO of Neurocrine ", "url": "https://www.investing.com/news/company-news/vir-biotechnology-appoints-timothy-coughlin-to-board-93CH-4736071", "source_name": "Investing.com", "published_at": "2026-06-11T11:09:55", "published_display": "11 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Vir Biotechnology, Inc. Reports Material Event", "summary": "Vir Biotechnology, Inc. has announced the appointment of Timothy Coughlin, CPA, to its Board of Directors, increasing the board size from seven to eight members. Coughlin will serve as a Class III director until the 2028 annual meeting and has also been appointed Chair of the Aud", "url": "https://www.stocktitan.net/sec-filings/VIR/8-k-vir-biotechnology-inc-reports-material-event-5ba7ed33efc7.html", "source_name": "Stock Titan", "published_at": "2026-06-10T20:39:21", "published_display": "10 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIR", "summary": "WINTON GROUP Ltd significantly increased its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by purchasing an additional 131,555 shares, bringing its total holding to 189,306 shares valued at approximately $1.14 million. This increased ownership comes despite Vir Biotechnology repo", "url": "https://www.marketbeat.com/instant-alerts/filing-winton-group-ltd-buys-131555-shares-of-vir-biotechnology-inc-vir-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T11:39:21", "published_display": "10 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIR News | VIR BIOTECHNOLOGY INC (NASDAQ:VIR)", "summary": "This article provides recent news and analysis for VIR Biotechnology Inc. (NASDAQ:VIR), including its stock price, recent appointments to its Board of Directors, upcoming clinical trial data presentations, and a report on its Q4 2025 revenue. The company is highlighted as a high-", "url": "https://www.chartmill.com/stock/quote/VIR/news", "source_name": "ChartMill", "published_at": "2026-06-08T23:09:00", "published_display": "08 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?", "summary": "The article summarizes a bullish thesis on Vir Biotechnology, Inc. (VIR) from Valueinvestorsclub.com, highlighting its lead asset VIR-5500 for metastatic castration-resistant prostate cancer. The therapy shows promising Phase 1 data with high response rates and reduced toxicity, ", "url": "https://www.insidermonkey.com/blog/is-vir-biotechnology-inc-vir-a-good-stock-to-buy-now-2-1769325/", "source_name": "Insider Monkey", "published_at": "2026-06-07T20:25:18", "published_display": "07 Jun 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIR Stock Surges 60% Pre-Market Today \u2013 Analysts Cheer Strong Cancer Data, Astellas Partnership", "summary": "Vir Biotechnology Inc. (VIR) saw its stock surge by 60% pre-market after strong fourth-quarter earnings, positive Phase 1 cancer therapy data for VIR-5500, and a new partnership with Astellas Pharma. Analysts responded with upgrades and increased price targets, signaling strong c", "url": "https://stocktwits.com/news-articles/markets/equity/vir-stock-surges-pre-market-today-analysts-cheer-strong-cancer-data-astellas-partnership/cZRvUqdR4C5", "source_name": "Stocktwits", "published_at": "2026-06-06T09:39:29", "published_display": "06 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/solstice-phase-2-hdv-data-141319894.html", "source_name": "Simply Wall St.", "published_at": "2026-05-24T14:13:19+00:00", "published_display": "24 May 2026 14:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million", "summary": "", "url": "https://finance.yahoo.com/m/8c90a4ee-398f-38da-a820-4129782190d6/vir-biotechnology-stock-has.html", "source_name": "Motley Fool", "published_at": "2026-05-18T15:19:55+00:00", "published_display": "18 May 2026 15:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNS2RIMmFnUXY3TzdpT2pnUVpkVktzcXhHWTNGZVB0TGE5N21KTFVGemZMLUlQWjAtalVGR1pZUWNFYzN4dnl3dy14OWo4T0Y3LVRodFFhSjRTajJQYW9DeHp5N3dtRFR6SGFDSWNiS1BUVXJkdVZiZllhRWhGdHdxbW9GTzN2N0pwZnBwV2VidGFCYjQyVFV1bXpUd1pEd2JyX2NRV29maVduNTVpQlRCTExHbVdLZzRqRkpsR252REMwQ1M2VEczTEpIdnhvUkRtcUlkYk9DYw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUTY4SzBROHBQYlRIT2Y0U2NWN1NHN0hlSkJHNXZMamhvN1dpRWVpNlZKb3I4UDAtOVZRS2dqNzRiTWZISUtTdlZVbldnZ3pfV1N0VXh0NWV0ckpMcUZGRDdaZGlXSEFZWktvdHVreUladmplcUJXLUpMYUxpMVBIOEJWSlJodnJhZjBHMlN6dF8zVUlRWHlHblFQZ3dNa1FWUDJ4eVVNMWVZZ0dVaWtsZEhBcTB2bFNROXE3VXFYQ3NJWXIxYjRYZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTXNUdVZadGlGUFRyY004aWwyQUQ1eUhVLVRxbUJtWTVrSndNdFV0S0xJYjdPTlhUVmNxVDl3Q2Y4VnE0d280bDh3QlFOOUNHS2JtRExnX0FfWHozeUNKVDhpRjJLbHZjdHdEQ0hldlRZbTFKdVNqWFEzRlFCbkNOclYweTJCcnNvXzFXWWVRWEhnSXVPbVJwSUJSbldKQlFXUF8zOTdKYlRxUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPS0FaVXlwSC1LNWdtS1EweXlZTlhzeDF6dWNvQUtRZm5qN1JCVHRZbzlUQ2I4RzBwMmQxTHhORTZ5MmVBLXlHTXprcnc1YWlrdWhiN2w3QzV0V0ozUDdaT0RLdkZrVlE0eFowUWJsRzhZckVOLVBVRjZPM2NxR1k0UTBGSnFSRUFoU2FfdUREQzA5VTZDRzZrWTBsU2xQYmV2M0NDVmpjRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQajdOSHprODFDWnVnMjZqMnc2Ynp0dEx2aHhSWV80dWtmRHU1Und5ZDJvRDZ1c1IyalhpYXo4UVlOVmNzdWoxS21JM0psajA4OTRnZFptOVVOYnYwaXRMYjNvdzZZRURoRmpnbGtsbGxsa0pIdjRmWUw2MjdyN2Rzb3JTb3BtTl9RLXJzM0QzYzF2cURTNW5PYXhISkNEeTZMZ3RkN3pyMTByZ3hVcEk4djYwSmVIUi1TZWJia2UtYXc3TDFja2lDY0pDLTRtX0xGX0lsV2VVZHNRU0hqTVNDX3VtZWjSAeoBQVVfeXFMTVd2bDZNajBqZV9rSlR0Mkc3bzdVMXFwa3hTcmY3SGhTNmQ2VTZ5Y29Iek81RTZYZGs5SkRTeG5RbXoxUmQwd04xSG1uOXVZMDVPMlZ0MGozTXpHOV9adGV6SnZZMzhsX3RObnJKRWcwSGVsVXBrdmpTTzBTV0txb2xmNWllVGR2UFV2MmV6S3JOcTFZbVc5SklqQi1wNVVoelRCb25pZHNvR0NyNVcxbU5UeGM0UVVlTmR0d0Rha3BnbzV1SzU3NWFyMzBIclBpd3hvRjhaeDcwTWNqWHpWNzFMX0l2NEsybjln?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPVW5oWHFqRi1BR1EycVByZzNmbXFLRk9PdEVNTnJLcTBkZmVyeWNseTFvSldzM01Ob2hUNnNjMWM4WUJDLXBaXzZ1R3NCNlFpV1lhaldoaEFTWVFpcnpxMkNLY1lrVGE5WWVwZmRiZFNSbFNHQ3psR3pjUmQ0YmpCR0RzeU5RYzhoamZkMmdfZUxXNVZ3SkFLSDJQRQ?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQQUhSUnNnbVE3UW5BYnFoRWRFRWZpby0zX1dONi1aZmx3X1Y4Z3pYdHF6b21VWFZjREZkWDEwZE82SUxUWWJGNGc3VnhTM0lGR2YwV2dEYUxxdG5DS1lQWDNjUnNqekRzOUZjX3RRYV9EaDFYb3l3ak0xdmczQ1IyZy11MTVzR1dRTTgtd1RkY1dTNDhaSkJ0N0MyakNMRFlP?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology closes $240M Astellas deal for cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQY240SFdwU2RNaTQ2N2pTanRRRktBcHdHZWJ0c2RNMmRrbkNVOG92TFktY2c3TGRlT1d4RFlQaXJFbGZhMkJZWlNTZGpSdi05UDBTa094M2V4cWtUbGo1MUJuQWlhQVh0MmM4VjNObnJsTjhTZFhNSTkydFZxcmNacEsxN1hocnZQVFNBZlRRSV9wb2NrTUpjODJNTnlQaDNMbWhfSnV6RW5KYXNsQlBBSUszalg0UmM?oc=5", "source_name": "Investing.com", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Rings the Nasdaq Stock Market Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNXzJkMFVnbUpnX3ZTWmllR3VhTHlFZlpPbzFCS2hyRGw2OHd4V0pjYV84WkpoN3RrN2VzNmhqbFlqY3U4bTZDbjkzZG51dE9XYW9VRlFoaWdKVjVLeVdQVnphcVNDLVBucVpRbUxOT3gzSGEtX1VlWlc3VDB3YWVVTmdsMUQ2MER2a2RtamZhcw?oc=5", "source_name": "Nasdaq", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latham & Watkins Advises on Vir Biotechnology\u2019s US$150 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQd09rRlNNUU85QTBjdXl1RnJfZ1pyTGx0blpGbGF5ZTZWS2U5am5QWUdWUEJxRFZ6UW53Nng3SkRuQ2hGV2ptTk5jd0ZMZ1VHMTZGRnpQdzRpM3hSQTM2NjBqazk0MUVWbXZBVlVvUnVxY2tzai16bTRtNFNlUkxoZmpHWHI3UE03X09Bd1QwaXBKay00ZzNCOXNYWQ?oc=5", "source_name": "Latham & Watkins LLP", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Announces Pricing of Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQaURfeVF1MVpmNGhSSDVYb0NqUWNHNmhrLTZaWENWTmZLOWJyQWd1QWxDSXYxLXMzS1A4Y1AyQnBRcUE3TXI2U1RQZ05CLXMzUVdEd2hrWEtpT2I2cktJTWZMQ3ZzVklPV2YwMndlYTFJOW9zeE14X2tXdVh4dW9BTHZ4ZVlmLXI3TWQ2dTg0WjJjejlyc0p2ZmtObDZOS2xRRHBrUXVOdkJ4eHBleklKSWFqdmN1ODBUNl8tVzhHQkhwaXJZYVE?oc=5", "source_name": "Business Wire", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSTljVXdEZDFkXzFGMnpDTVZLaEhtRFlic0NKbnhWcUtQTXBnMTZ6QW1JNzRIUmxqZ1RMTXJVS1BXSkliMUFIQzcxREpha3VEczZhWkp1WUFXRkRjRDliOU9LZnduUVlPN2dzU3N2WF9lYVp3Z29odGY1VFBEbDhDMmpDTWo2YlBQelZ5cWh0Q1phUDZycUhqcmZPdlBWZThLVVFoeTFHbHFyQmdoWTRpa3BQaUpYbGNfWm9fOVJkSDNQUUk?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOTlBxUW9QV2o3YTF4RVdzWWlWUWZfU2V6Y25mcHBxM2RQTkpES0FqY0xsRDdtc0NqZE1KY2RFSWFfMGVCSVR2RXpndERPOFF6al9HQndCU2p0SkpPQ3dsc19BaVVvSzFxQ2FwcGEwVFlxNUFmZUUtdHpvVmpfQkFDX2FVLXprUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. $VIR Shares Bought by Candriam S.C.A.", "summary": "Candriam S.C.A. increased its stake in Vir Biotechnology (NASDAQ:VIR) by 10.1% in the first quarter, holding over 1.1 million shares valued at approximately $10.2 million. Other institutional investors also adjusted their positions, resulting in 65.32% institutional ownership. Wh", "url": "https://www.marketbeat.com/instant-alerts/filing-vir-biotechnology-inc-vir-shares-bought-by-candriam-sca-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T08:40:38", "published_display": "13 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Y Intercept Hong Kong Ltd Takes Position in Vir Biotechnology, Inc. $VIR", "summary": "Y Intercept Hong Kong Ltd disclosed a new position in Vir Biotechnology, Inc. by purchasing 134,547 shares valued at approximately $1.2 million, now owning 0.08% of the company. Vir Biotechnology shares recently traded down, sitting below its 52-week high, and the company reporte", "url": "https://www.marketbeat.com/instant-alerts/filing-y-intercept-hong-kong-ltd-takes-position-in-vir-biotechnology-inc-vir-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T18:38:59", "published_display": "12 Jul 2026 18:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Vir Biotechnology, Inc. (VIR)", "summary": "This article analyzes the historical stock performance of Vir Biotechnology, Inc. (VIR). It calculates the returns on hypothetical $1,000 investments made one and five years ago, showing disparate outcomes. The article also provides an overview of Vir Biotechnology's focus on inf", "url": "https://www.stocktitan.net/tools/stock-return-calculator/VIR", "source_name": "Stock Titan", "published_at": "2026-07-04T09:09:43", "published_display": "04 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SA", "summary": "Pictet Asset Management Holding SA significantly increased its stake in Vir Biotechnology (NASDAQ:VIR) by 10,878.9% in Q1, now owning 1.48 million shares worth $13.3 million. This increase comes despite Vir Biotechnology reporting weaker than expected quarterly results and analys", "url": "https://www.marketbeat.com/instant-alerts/filing-vir-biotechnology-inc-vir-stock-holdings-increased-by-pictet-asset-management-holding-sa-2026-07-03/", "source_name": "MarketBeat", "published_at": "2026-07-03T09:11:13", "published_display": "03 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIR - Vir Biotechnology Inc Latest SEC Filings", "summary": "This page provides an overview of Vir Biotechnology Inc (VIR) focusing on its latest SEC filings and comprehensive financial data. It includes key stock performance metrics, valuation ratios, and insider/institutional ownership percentages, alongside recent earnings figures and a", "url": "https://finviz.com/stock?t=VIR&p=m&ty=lf&r=max&page=13", "source_name": "Finviz", "published_at": "2026-07-02T11:11:49", "published_display": "02 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Announces Proposed Public Offering of Common Stock", "summary": "Vir Biotechnology, a clinical-stage biopharmaceutical company, announced its intention to offer $200,000,000 of common stock in an underwritten public offering. The company will also grant underwriters a 30-day option to purchase an additional $30,000,000 of shares. The offering ", "url": "https://www.natlawreview.com/press-releases/vir-biotechnology-announces-proposed-public-offering-common-stock", "source_name": "The National Law Review", "published_at": "2026-07-01T08:10:02", "published_display": "01 Jul 2026 08:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Vir Biotechnology For: 29 June By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing by Vir Biotechnology for June 29. It includes the stock symbol VIR and its performance on that date, amidst various market data and other news. The content primarily serves as a placeholder for the filing information, a", "url": "https://ng.investing.com/news/stock-market-news/form-144-vir-biotechnology-for-29-june-93CH-2578668", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T19:39:26", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OP Asset Management Ltd Takes Position in Vir Biotechnology, Inc. $VIR", "summary": "OP Asset Management Ltd has acquired a new position in Vir Biotechnology, purchasing 113,028 shares valued at approximately $1.013 million in the first quarter of 2026. This move comes as institutional investors now own 65.32% of the company's shares. Despite a recent weak quarte", "url": "https://www.marketbeat.com/instant-alerts/filing-op-asset-management-ltd-takes-position-in-vir-biotechnology-inc-vir-2026-06-30/", "source_name": "MarketBeat", "published_at": "2026-06-30T09:09:54", "published_display": "30 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Vir Biotechnology, Inc. SEC Filing", "summary": "This article reports on Vir Biotechnology, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details include the sale of 16,000 shares of common stock acquired through a stock option exercise, with an aggregate market value of $165,138.95, and ", "url": "https://www.stocktitan.net/sec-filings/VIR/144-vir-biotechnology-inc-sec-filing-c016dfa796b3.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:40:30", "published_display": "29 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Vir Biotechnology, Inc. \u2013 NASDAQ:VIR", "summary": "This article provides financial information for Vir Biotechnology, Inc. (NASDAQ: VIR), specifically focusing on its forward price-to-sales ratio. It appears to be a financial data point or a report generated by TradingView, detailing a specific period's value, change, and percent", "url": "https://www.tradingview.com/symbols/NASDAQ-VIR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:24", "published_display": "26 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Vir Biotechnology, Inc. (VIR) stock, including analyst price targets, current stock performance, and financial data. It highlights that the 9 analysts have a price target of 21.56 USD with a maximum estimate of 30.00 USD and a minimum of 16.00", "url": "https://www.tradingview.com/symbols/NASDAQ-VIR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:23", "published_display": "26 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Vir Biotechnology, Inc. \u2013 NASDAQ:VIR", "summary": "This article focuses on the enterprise value to EBIT forward metric for Vir Biotechnology, Inc. (NASDAQ: VIR). It directly presents the financial data for this specific metric without further analysis or commentary within the provided content. The details are presented in a strai", "url": "https://www.tradingview.com/symbols/NASDAQ-VIR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:09:37", "published_display": "26 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIR: Hepatitis Delta Program And Oncology Partnership Will Drive Future Upside", "summary": "Analysts have increased their average price target for Vir Biotechnology to $21.56, up from $20.67, driven by an improved revenue growth outlook and a higher future P/E assumption, factoring in the potential of emerging hepatitis delta virus therapies. The company is advancing in", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/p3tydi5d-strong-clinical-advances-in-oncology-and-hepatitis-delta-will-secure-future-success/updates/17-analysts-have-lifted-the-average-price-target-for-vir-biotec", "source_name": "Simply Wall Street", "published_at": "2026-06-23T17:09:37", "published_display": "23 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Inc (VIR) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Vir Biotechnology Inc (VIR) has a current risk assessment score of 4.70, placing it 67th out of 389 in the Biotechnology & Medical Research industry. The company's beta of 1.66 indicates higher volatility compared to the S&P 500. The report details various risk metrics including ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vir/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-23T08:40:53", "published_display": "23 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Inc (VIR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Vir Biotechnology Inc (VIR), giving it a current financial score of 7.47, ranking it 116 out of 389 in its industry. The company shows stable financial status and high operating efficiency. However, its latest quarterly revenue decrea", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vir/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T08:09:48", "published_display": "23 Jun 2026 08:09", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of \"Moderate Buy\" by Brokerages", "summary": "Vir Biotechnology, Inc. (NASDAQ:VIR) has received a consensus \"Moderate Buy\" rating from nine brokerages, with an average 1-year price target of $20.88. Recent analyst updates were largely positive, including increased price targets from several firms, though Weiss Ratings mainta", "url": "https://www.marketbeat.com/instant-alerts/vir-biotechnology-inc-nasdaqvir-given-average-recommendation-of-moderate-buy-by-brokerages-2026-06-22/", "source_name": "MarketBeat", "published_at": "2026-06-22T06:39:24", "published_display": "22 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology (VIR) Stock Could Be 56% Undervalued After New PSMA Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOVTJhTXA4amtuREtjcW5TR1dBRTlUWW5EcDNuT0tqUHNoN0FqWXNfQ3BVRjczVWJIbXZZY2hPQjV2d1A2cEVDX0o0TVZKRl9NY0FqeThubDlSZkNlU3ItdmNwNV9wV0dkdVVzWkdjelJyMkNzZzIwZDVzN2lqMnRLYkJFZzlVZkV5RzZIMF9WdllFX0JEMXczUC0wMUhQMFNJQUwyeVY4dUN5M3I0dU1jN3p3SUVIMU1xaXhmRzhveDIwV0k4NXVmcnQycGJRMGxxbjRmLVRGYVRzNmlzaG1wX0tYeW_SAeoBQVVfeXFMT2plSEpSQ0RSaFRERjU4bFdYN01KdWhyd0YtMV9Dbko3bjhVaFRhQ3R0bnlGVEZmSzBzRC1KUTRqVFduUENrcDd4Vms3ZHYySXdsTVlnSXo5ekIycVZuS1B0SGRxVXB6U3VKSWxvN1dZSldtVm1UeFlicFVDLUpLSDNjWHdiVnhRZ0hodVpodDZGdmV4T2tYR2VoVTRERDJ6NTZsSlpfbHNucy1xQnFGQ2NBaTQzTWo5NkgzM2daU3R0WUYzalpJT2VSTVRFRTdfOGpyNWdlQUJGWWZQZHJLWUY3ODFmXzIwclFn?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vir Biotechnology (VIR) Quietly Recasting Its Governance Strength With a New Audit Committee Chair?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTFBLTlZKRkozaEk4eERFcjZIb0ZibktCNnJNSkVzdmhCd0ZFRzROcll0TjJiTVBqeG5iWlhlSlFybFdsdkV4Qkw5RFB5Wmd5MDBkbFZ2Z1NZX1ZfV1pxcGNjZFk1dEZjR21FRWNUQ2RqOA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T05:53:20+00:00", "published_display": "18 Jun 2026 05:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Vir Biotechnology Inc (VIR), noting that relevant data for business segments, regional revenue, and profit contribution for FY2025 has not yet been disclosed by the company. It indicates that the United States contribu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vir/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T05:11:06", "published_display": "17 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants", "summary": "Vir Biotechnology director Timothy Coughlin has been granted restricted stock units (RSUs) and stock options. He received two RSU awards of 8,000 shares each and two stock option grants covering 16,000 shares each, with an exercise price of $8.51 per share, expiring in 2036. Thes", "url": "https://www.stocktitan.net/sec-filings/VIR/form-4-vir-biotechnology-inc-insider-trading-activity-f2f5d00ba14f.html", "source_name": "Stock Titan", "published_at": "2026-06-12T17:09:37", "published_display": "12 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology (VIR) director Coughlin reports zero share ownership", "summary": "Vir Biotechnology director Timothy Coughlin filed an initial Form 3, reporting zero beneficial ownership of the company's common stock as of June 9, 2026. This SEC filing establishes his initial position as an insider, showing no direct holdings. A Form 3 is required when an indi", "url": "https://www.stocktitan.net/sec-filings/VIR/form-3-vir-biotechnology-inc-initial-statement-of-beneficial-ownershi-09a23817212a.html", "source_name": "Stock Titan", "published_at": "2026-06-11T22:40:06", "published_display": "11 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00", "summary": "Morgan Stanley has increased its price target for Vir Biotechnology (NASDAQ:VIR) to $27.00 from $23.00, maintaining an \"overweight\" rating. This adjustment suggests a potential upside of 227.27% from the current stock price. Despite weak recent earnings, insider selling, and mixe", "url": "https://www.marketbeat.com/instant-alerts/morgan-stanley-raises-vir-biotechnology-nasdaqvir-price-target-to-2700-2026-06-11/", "source_name": "MarketBeat", "published_at": "2026-06-11T13:09:00", "published_display": "11 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors", "summary": "Vir Biotechnology, Inc. announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. Mr. Coughlin, former CFO of Neurocrine Biosciences, Inc., brings extensive financial and operational experience across the ", "url": "https://www.businesswire.com/news/home/20260610324261/en/Vir-Biotechnology-Announces-Appointment-of-Timothy-Coughlin-to-its-Board-of-Directors", "source_name": "Business Wire", "published_at": "2026-06-11T11:39:33", "published_display": "11 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology appoints Timothy Coughlin to board", "summary": "Vir Biotechnology (NASDAQ:VIR) has announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026. Coughlin brings extensive financial and biotechnology experience, having previously served as CFO of Neurocrine ", "url": "https://www.investing.com/news/company-news/vir-biotechnology-appoints-timothy-coughlin-to-board-93CH-4736071", "source_name": "Investing.com", "published_at": "2026-06-11T11:09:55", "published_display": "11 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Vir Biotechnology, Inc. Reports Material Event", "summary": "Vir Biotechnology, Inc. has announced the appointment of Timothy Coughlin, CPA, to its Board of Directors, increasing the board size from seven to eight members. Coughlin will serve as a Class III director until the 2028 annual meeting and has also been appointed Chair of the Aud", "url": "https://www.stocktitan.net/sec-filings/VIR/8-k-vir-biotechnology-inc-reports-material-event-5ba7ed33efc7.html", "source_name": "Stock Titan", "published_at": "2026-06-10T20:39:21", "published_display": "10 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIR", "summary": "WINTON GROUP Ltd significantly increased its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by purchasing an additional 131,555 shares, bringing its total holding to 189,306 shares valued at approximately $1.14 million. This increased ownership comes despite Vir Biotechnology repo", "url": "https://www.marketbeat.com/instant-alerts/filing-winton-group-ltd-buys-131555-shares-of-vir-biotechnology-inc-vir-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T11:39:21", "published_display": "10 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIR News | VIR BIOTECHNOLOGY INC (NASDAQ:VIR)", "summary": "This article provides recent news and analysis for VIR Biotechnology Inc. (NASDAQ:VIR), including its stock price, recent appointments to its Board of Directors, upcoming clinical trial data presentations, and a report on its Q4 2025 revenue. The company is highlighted as a high-", "url": "https://www.chartmill.com/stock/quote/VIR/news", "source_name": "ChartMill", "published_at": "2026-06-08T23:09:00", "published_display": "08 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?", "summary": "The article summarizes a bullish thesis on Vir Biotechnology, Inc. (VIR) from Valueinvestorsclub.com, highlighting its lead asset VIR-5500 for metastatic castration-resistant prostate cancer. The therapy shows promising Phase 1 data with high response rates and reduced toxicity, ", "url": "https://www.insidermonkey.com/blog/is-vir-biotechnology-inc-vir-a-good-stock-to-buy-now-2-1769325/", "source_name": "Insider Monkey", "published_at": "2026-06-07T20:25:18", "published_display": "07 Jun 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIR Stock Surges 60% Pre-Market Today \u2013 Analysts Cheer Strong Cancer Data, Astellas Partnership", "summary": "Vir Biotechnology Inc. (VIR) saw its stock surge by 60% pre-market after strong fourth-quarter earnings, positive Phase 1 cancer therapy data for VIR-5500, and a new partnership with Astellas Pharma. Analysts responded with upgrades and increased price targets, signaling strong c", "url": "https://stocktwits.com/news-articles/markets/equity/vir-stock-surges-pre-market-today-analysts-cheer-strong-cancer-data-astellas-partnership/cZRvUqdR4C5", "source_name": "Stocktwits", "published_at": "2026-06-06T09:39:29", "published_display": "06 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/solstice-phase-2-hdv-data-141319894.html", "source_name": "Simply Wall St.", "published_at": "2026-05-24T14:13:19+00:00", "published_display": "24 May 2026 14:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million", "summary": "", "url": "https://finance.yahoo.com/m/8c90a4ee-398f-38da-a820-4129782190d6/vir-biotechnology-stock-has.html", "source_name": "Motley Fool", "published_at": "2026-05-18T15:19:55+00:00", "published_display": "18 May 2026 15:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNS2RIMmFnUXY3TzdpT2pnUVpkVktzcXhHWTNGZVB0TGE5N21KTFVGemZMLUlQWjAtalVGR1pZUWNFYzN4dnl3dy14OWo4T0Y3LVRodFFhSjRTajJQYW9DeHp5N3dtRFR6SGFDSWNiS1BUVXJkdVZiZllhRWhGdHdxbW9GTzN2N0pwZnBwV2VidGFCYjQyVFV1bXpUd1pEd2JyX2NRV29maVduNTVpQlRCTExHbVdLZzRqRkpsR252REMwQ1M2VEczTEpIdnhvUkRtcUlkYk9DYw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUTY4SzBROHBQYlRIT2Y0U2NWN1NHN0hlSkJHNXZMamhvN1dpRWVpNlZKb3I4UDAtOVZRS2dqNzRiTWZISUtTdlZVbldnZ3pfV1N0VXh0NWV0ckpMcUZGRDdaZGlXSEFZWktvdHVreUladmplcUJXLUpMYUxpMVBIOEJWSlJodnJhZjBHMlN6dF8zVUlRWHlHblFQZ3dNa1FWUDJ4eVVNMWVZZ0dVaWtsZEhBcTB2bFNROXE3VXFYQ3NJWXIxYjRYZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTXNUdVZadGlGUFRyY004aWwyQUQ1eUhVLVRxbUJtWTVrSndNdFV0S0xJYjdPTlhUVmNxVDl3Q2Y4VnE0d280bDh3QlFOOUNHS2JtRExnX0FfWHozeUNKVDhpRjJLbHZjdHdEQ0hldlRZbTFKdVNqWFEzRlFCbkNOclYweTJCcnNvXzFXWWVRWEhnSXVPbVJwSUJSbldKQlFXUF8zOTdKYlRxUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPS0FaVXlwSC1LNWdtS1EweXlZTlhzeDF6dWNvQUtRZm5qN1JCVHRZbzlUQ2I4RzBwMmQxTHhORTZ5MmVBLXlHTXprcnc1YWlrdWhiN2w3QzV0V0ozUDdaT0RLdkZrVlE0eFowUWJsRzhZckVOLVBVRjZPM2NxR1k0UTBGSnFSRUFoU2FfdUREQzA5VTZDRzZrWTBsU2xQYmV2M0NDVmpjRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPVW5oWHFqRi1BR1EycVByZzNmbXFLRk9PdEVNTnJLcTBkZmVyeWNseTFvSldzM01Ob2hUNnNjMWM4WUJDLXBaXzZ1R3NCNlFpV1lhaldoaEFTWVFpcnpxMkNLY1lrVGE5WWVwZmRiZFNSbFNHQ3psR3pjUmQ0YmpCR0RzeU5RYzhoamZkMmdfZUxXNVZ3SkFLSDJQRQ?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQQUhSUnNnbVE3UW5BYnFoRWRFRWZpby0zX1dONi1aZmx3X1Y4Z3pYdHF6b21VWFZjREZkWDEwZE82SUxUWWJGNGc3VnhTM0lGR2YwV2dEYUxxdG5DS1lQWDNjUnNqekRzOUZjX3RRYV9EaDFYb3l3ak0xdmczQ1IyZy11MTVzR1dRTTgtd1RkY1dTNDhaSkJ0N0MyakNMRFlP?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology closes $240M Astellas deal for cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQY240SFdwU2RNaTQ2N2pTanRRRktBcHdHZWJ0c2RNMmRrbkNVOG92TFktY2c3TGRlT1d4RFlQaXJFbGZhMkJZWlNTZGpSdi05UDBTa094M2V4cWtUbGo1MUJuQWlhQVh0MmM4VjNObnJsTjhTZFhNSTkydFZxcmNacEsxN1hocnZQVFNBZlRRSV9wb2NrTUpjODJNTnlQaDNMbWhfSnV6RW5KYXNsQlBBSUszalg0UmM?oc=5", "source_name": "Investing.com", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Rings the Nasdaq Stock Market Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNXzJkMFVnbUpnX3ZTWmllR3VhTHlFZlpPbzFCS2hyRGw2OHd4V0pjYV84WkpoN3RrN2VzNmhqbFlqY3U4bTZDbjkzZG51dE9XYW9VRlFoaWdKVjVLeVdQVnphcVNDLVBucVpRbUxOT3gzSGEtX1VlWlc3VDB3YWVVTmdsMUQ2MER2a2RtamZhcw?oc=5", "source_name": "Nasdaq", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latham & Watkins Advises on Vir Biotechnology\u2019s US$150 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQd09rRlNNUU85QTBjdXl1RnJfZ1pyTGx0blpGbGF5ZTZWS2U5am5QWUdWUEJxRFZ6UW53Nng3SkRuQ2hGV2ptTk5jd0ZMZ1VHMTZGRnpQdzRpM3hSQTM2NjBqazk0MUVWbXZBVlVvUnVxY2tzai16bTRtNFNlUkxoZmpHWHI3UE03X09Bd1QwaXBKay00ZzNCOXNYWQ?oc=5", "source_name": "Latham & Watkins LLP", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Announces Pricing of Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQaURfeVF1MVpmNGhSSDVYb0NqUWNHNmhrLTZaWENWTmZLOWJyQWd1QWxDSXYxLXMzS1A4Y1AyQnBRcUE3TXI2U1RQZ05CLXMzUVdEd2hrWEtpT2I2cktJTWZMQ3ZzVklPV2YwMndlYTFJOW9zeE14X2tXdVh4dW9BTHZ4ZVlmLXI3TWQ2dTg0WjJjejlyc0p2ZmtObDZOS2xRRHBrUXVOdkJ4eHBleklKSWFqdmN1ODBUNl8tVzhHQkhwaXJZYVE?oc=5", "source_name": "Business Wire", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSTljVXdEZDFkXzFGMnpDTVZLaEhtRFlic0NKbnhWcUtQTXBnMTZ6QW1JNzRIUmxqZ1RMTXJVS1BXSkliMUFIQzcxREpha3VEczZhWkp1WUFXRkRjRDliOU9LZnduUVlPN2dzU3N2WF9lYVp3Z29odGY1VFBEbDhDMmpDTWo2YlBQelZ5cWh0Q1phUDZycUhqcmZPdlBWZThLVVFoeTFHbHFyQmdoWTRpa3BQaUpYbGNfWm9fOVJkSDNQUUk?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOTlBxUW9QV2o3YTF4RVdzWWlWUWZfU2V6Y25mcHBxM2RQTkpES0FqY0xsRDdtc0NqZE1KY2RFSWFfMGVCSVR2RXpndERPOFF6al9HQndCU2p0SkpPQ3dsc19BaVVvSzFxQ2FwcGEwVFlxNUFmZUUtdHpvVmpfQkFDX2FVLXprUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 90, "total_relevant": 59, "sentiment_summary": {"positive": 9, "negative": 7, "neutral": 43, "score": 51, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 13.2, "count": 24}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 9.96, "latest_week": "2026-07-10", "one_week_move": -0.8, "four_week_move": 15.7, "twelve_week_move": -7.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.167071, "market_dynamics_buy_signal": false, "relative_strength": 19.516908, "fair_value_gap": 19.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.087, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.8% over one week, +15.7% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 48, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "MarketBeat", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Business Wire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 59}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 24}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 3}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "59", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.8% over one week, +15.7% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks"}], "updated_at": "2026-07-16T06:04:37.421373+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}